《原发性肝癌诊疗规范(2017年版)》更新要点解读

我国于2011年发布的《原发性肝癌诊疗规范》有效提高了肝癌的综合诊治水平。最新发布的《原发性肝癌诊疗规范（2017年版）》在2011年版的基础上，首次引入了循证医学证据等级，规范了肝癌病理取材方法，引入了微血管侵犯的概念作为病理常规报告项目，通过实体瘤疗效评价标准修订版（mRECIST）评价抗肿瘤治疗疗效，并根据我国实际情况，提出了我国的肝癌临床分期和治疗路径。本文试对《原发性肝癌诊疗规范（2017年版）》的更新要点进行解读，供同行参考。
The Standardization of Diagnosis and Treatment for Hepatocellular Carcinoma issued by China in 2011 has effectively improved the comprehensive diagnosis and treatment of hepatocellular carcinoma (HCC). The new edition of Standardization of Diagnosis and Treatment for Hepatocellular Carcinoma published in 2017 firstly introduced the Oxford Centre for Evidence Based Medicine (OCEBM) grades of evidence, standardized the sampling method of HCC, and emphasized microvascular invasion (MVI) as an indicator of regular pathology report. The new guideline recommends modified Response Evaluation Criteria in Solid Tumor (mR ECIST) to assess anti-tumor efficiency. Moreover, the new guideline presents the Chinese staging system and treatment roadmap for HCC according to Chinese actual situation. This paper aimed to interpret the updates of the new guideline for reference by colleagues